Daiichi Sankyo and AstraZeneca’s Enhertu has been approved in the European Union, or EU, as monotherapy indicated for the treatment of adult patients with unresectable or metastatic HER2 low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- Novartis downgraded to Neutral from Buy at Citi
- Thermo Fisher, AstraZeneca team on CDx test for Tagrisso
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- AstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share
- Biotech Alert: Searches spiking for these stocks today